RE: $2bn sales per annum for STS .....29 Aug 2023 14:11
One more time wynbore from the very first rns on ava6000 trial
"This trial of AVA6000 is a dose-escalation Phase I study in patients with locally advanced or metastatic selected solid tumours, known to be FAP-positive, in which cohorts of patients receive ascending doses of AVA6000 to determine the maximum tolerated dose and establish a recommended Phase II dose."